On the other hand high expression of epsin (EPN3) with its well-established role in tumor angiogenesis, conferring worse prognosis in breast and lung cancer, is of high clinical relevance considering the ongoing development of epsin antagonizing therapies. This evidence concerns the gene EPN3 and lung cancer.